Sonnet BioTherapeutics
PURRPURR · Stock Price
Historical price data
Overview
Sonnet BioTherapeutics is a clinical-stage biotech focused on developing targeted immunotherapies using its proprietary Fully Human Albumin-Binding (FHAB™) technology platform. Its mission is to improve the safety and efficacy of cytokine therapies for cancer and peripheral neuropathies by leveraging the body's natural albumin transport system. A key strategic achievement was the December 2025 business combination with Hyperliquid Strategies Inc., creating a Nasdaq-listed entity (PURR) with a dual operational model combining biotech R&D with digital asset treasury management. The company's strategy centers on advancing its modular pipeline through internal development and strategic collaborations.
Technology Platform
Proprietary FHAB™ (Fully Human Albumin-Binding) platform uses a human single-chain antibody fragment (scFv) to bind drugs to circulating albumin, enabling targeted delivery to tumors and inflamed tissues with extended half-life.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| SON-080 | Chemotherapy-induced Peripheral Neuropathy (CIPN) | Phase 1/2 | |
| SON-1010 | Advanced Solid Tumor | Phase 1/2 | |
| SON-1010 (IL12-FHAB) | Healthy Adult | Phase 1 | |
| SON-1010 | Advanced Solid Tumor | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Sonnet competes with other firms developing targeted cytokine therapies (e.g., Alkermes, Werewolf Therapeutics) in a crowded immuno-oncology field. Its hybrid biotech/digital asset corporate structure is unique, presenting both a potential strategic advantage and a significant complexity with no direct peers.